Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Evaxion Biotech ( (EVAX) ) is now available.
On February 14, 2025, Evaxion Biotech announced that Nasdaq confirmed its full compliance with the minimum stockholders’ equity requirement, withdrawing the previous delisting determination. This development follows Evaxion’s successful capital market activities that bolstered its equity and extended its cash runway to mid-2026. The company’s equity position is expected to further improve with the anticipated conversion of its EIB loan to equity in the first quarter of 2025, solidifying its financial stability and enabling it to focus on its strategic milestones for the year.
More about Evaxion Biotech
Evaxion Biotech A/S is a pioneering TechBio company based in Denmark that specializes in developing vaccines powered by AI-Immunology™. The company leverages its proprietary AI prediction models to create novel immunotherapies targeting cancer, bacterial diseases, and viral infections, with a focus on addressing high unmet medical needs.
YTD Price Performance: -38.30%
Average Trading Volume: 2,377,324
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.06M
See more insights into EVAX stock on TipRanks’ Stock Analysis page.
